Insider selling
Traded Dec 23, 2024 · filed 4 days laterNot reported under a pre-arranged trading plan
A major shareholder of Stoke Therapeutics sold $23M of Stoke Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Dec 6, 2024 · Filed Dec 11, 2024
Stoke Therapeutics's GENERAL COUNSEL & CORP SEC sold $124K of Stoke Therapeutics shares. The filing references tax withholding.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$123,891
Shares × reported transaction price
31 days after results of Nov 5, 2024, 102 days before results of Mar 18, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
Insider selling
Traded Dec 23, 2024 · filed 4 days laterNot reported under a pre-arranged trading plan
A major shareholder of Stoke Therapeutics sold $23M of Stoke Therapeutics shares. The filing does not indicate a pre-arranged trading plan.
Edward M. Md Kaye (CEO) sold ~$79K of Stoke Therapeutics
Automatic saleBarry Ticho (CHIEF MEDICAL OFFICER) sold ~$178K of Stoke Therapeutics
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.